Unexpectedly high frequency of European parentage in Venezuelan patients with chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 2, 2012, Pages 235-241

  Marquez, Maria Elena ^a   Deglesne, Pierre Antoine ^a   Lopez, Jose Luis ^b   Costa, Osiris Da ^b   Borrego, Mildred ^b   Hernndez, Marcos ^c   Muller, Aixa ^d   Ajchenbaum Cymbalista, Florence ^e   Romano, Egidio ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b Banco Munic Sangre Distrito F   (Venezuela)

^c Hospital Central de Valencia   (Venezuela)

^d Clinica El Avila   (Venezuela)

^e AVICENNE HOSPITAL   (France)

Author keywords

CD38 antigen; Chronic lymphocytic leukemia; IGVH mutational status; ZAP 70

Indexed keywords

CD38 ANTIGEN; PROTEIN KINASE ZAP 70;

ADULT; AGED; ARTICLE; CAUCASIAN; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENTARITY DETERMINING REGION; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN VARIABLE REGION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; OUTCOME ASSESSMENT; PARENTHOOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SOUTH AND CENTRAL AMERICA; VENEZUELA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; COMPLEMENTARITY DETERMINING REGIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VENEZUELA; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84856114803     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.606938     Document Type: Article

References (34)

1. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008;112:1923-1930.
2. Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic signifi cance. Cancer 1977;40:855-864. (Pubitemid 8177910)
3. Rai KR, Sawitsky A, Cronkite EP. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
4. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847. (Pubitemid 29430399)
5. Durig J, Naschar M, Schmucker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002;16:30-35. (Pubitemid 34105596)
6. C respo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775. (Pubitemid 36514707)
7. Duke VM, Gandini D, Sherrington PD, et al. V(H) gene usage diff ers in germline and mutated B-cell chronic lymphocytic leukemia. Haematologica 2003;88:1259-1271. (Pubitemid 37456381)
8. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901. (Pubitemid 39096916)
9. H amblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854. (Pubitemid 29430400)
10. Maloum K, Davi F, Merle-Beral H, et al. Expression of unmutated V(H) genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 2000;96:377-379. (Pubitemid 30456502)
11. Morilla A, Gonzalez de Castro D, Del Giadice I, et al. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to fi rst treatment in CLL. Leuk Lymphoma 2008;49:2108-2115.
12. Tobin G, Th unberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003;101:4952-4957. (Pubitemid 36857759)
13. W idhopf GF, Rassenti LZ, Toy TL, et al. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004;104:2499-2504. (Pubitemid 39331853)
14. Chen L, Zhang Y, Zheng W, et al. Distinctive IGVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008;32:1491-1498.
15. H ojjat Farsangi M, Jeddi-Tehrani M, Razavi SM, et al. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia. Cancer Sci 2009;100:2346-2353.
16. H ojjat Farsangi M, Jeddi-Tehrani M, Sharifi an RA, et al. Analysis of the immunoglobulin heavy chain variable region gene expression in Iranian patients with choronic lymphocytic leukemia. Leuk Lymphoma 2006;48:109-116.
17. Koiso H, Yamane A, Mitsui T, et al. Distinctive immunoglobulin VH gene usage in Japanese patients with chronic lymphocytic leukemia. Leuk Res 2006;30:272-276. (Pubitemid 43053221)
18. Boggs DR, Chen SC, Zhang ZN, et al. Chronic lymphocytic leukemia in China. Am J Hematol 1987;25:349-354. (Pubitemid 17103190)
19. Gale RP, Cozen W, Goodman MT, et al. Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. Leuk Res 2000;24:665-669. (Pubitemid 30495500)
20. Irons RD, Le A, Bao L, et al. Characterization of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Shanghai, China: molecular and cytogenetic characteristics, IgV gene restriction and hypermutation patterns. Leuk Res 2009;33:1599-1603.
21. Ruiz-Arguelles GJ, Velazquez BM, Apreza-Molina MG, et al. Chronic lymphocytic leukemia is frequent in Mexican mestizos. Int J Hematol 1999;69:253-255.
22. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute- Sponsored Working Group Guidelines for Chronic Lymphocytic Leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997. (Pubitemid 26189840)
23. Deglesne PA, Chevallier N, Letestu R, et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Res 2006;66:7158-7166. (Pubitemid 44197694)
24. Marquez ME, Deglesne PA, Suarez G, et al. MFI ratio estimation of ZAP-70 in B-CLL by fl ow cytometry can be improved by considering the isotype-matched antibody signal. Int J Lab Hematol 2010;33:194-200.
25. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008;111:1524-1533. (Pubitemid 351213442)
26. Nardini E, Neri F, Vicenzi E, et al. Th ymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. Int J Cancer 2003;107:958-961. (Pubitemid 37429837)
27. Tobin G, Th unberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004;104:2879-2885. (Pubitemid 39434975)
28. Crowther-Swanepoel D, Wild R, Sellick G, et al. Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IGVH gene usage and mutation status in familial CLL. Blood 2008;111:5691-5693.
29. Messmer BT, Raphael BJ, Aerni SJ, et al. Computational identifi cation of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res 2009;33:368-376.
30. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007;109:259-270. (Pubitemid 46070124)
31. Martinez H, Rodriguez-Larralde A, Izaguirre MH, et al. Admixture estimates for Caracas, Venezuela, based on autosomal, Y-chromosome, and mtDNA markers. Hum Biol 2007;79:201-213. (Pubitemid 47623778)
32. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patters and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005;105:1678-1685. (Pubitemid 40223690)
33. Tobin G, Th unberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:2262-2264. (Pubitemid 34525519)
34. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status Blood 2006;107:2889-2894.